# 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

> **NCT02115204** · PHASE3 · COMPLETED · sponsor: **West German Study Group** · enrollment: 2011 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Methotrexate
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT02115204
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2005-08
- **Final completion:** 2010-08
- **Target enrollment:** 2011 (ACTUAL)
- **Last updated:** 2019-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115204, "4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02115204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*